Get the Stockscreener App
1.28
0.79%
0.01
An 2 Therapeutics Inc stock is traded at $1.28, with a volume of 3,470.
It is up +0.79% in the last 24 hours and up +16.36% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
See More
Previous Close:
$1.27
Open:
$1.29
24h Volume:
3,470
Relative Volume:
0.04
Market Cap:
$34.98M
Revenue:
-
Net Income/Loss:
$-37.38M
P/E Ratio:
-1.0323
EPS:
-1.24
Net Cash Flow:
$-35.50M
1W Performance:
+0.39%
1M Performance:
+16.36%
6M Performance:
-7.25%
1Y Performance:
+21.90%
1-Day Range:
$1.2643
$1.32
1-Week Range:
$1.212
$1.38
52-Week Range:
$0.975
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Compare ANTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.28 | 34.70M | 0 | -37.38M | -35.50M | -1.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
404.37 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.00 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.88 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
770.12 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.98 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial - MSN
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
United Therapeutics' TETON-2 Trial Shows Success in IPF Treatment | UTHR Stock News - Stock Titan
skip to main content - United Therapeutics Investor Relations
Shareholders of Unicycive Therapeutics, Inc. Should Contact - GlobeNewswire
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome - The Malaysian Reserve
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes - FinancialContent
Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results - MSN
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - The Manila Times
Kyverna Therapeutics to Highlight Interim Phase 2 Data from - GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA - GlobeNewswire
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - sg.finance.yahoo.com
Defence Therapeutics Inc. announced that it has received CAD 2 million in funding - MarketScreener
Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - sg.finance.yahoo.com
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewswire
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 - Business Wire
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewswire
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent (NASDAQ:MNPR) - Seeking Alpha
Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease Treatment - Quiver Quantitative
Hoth Therapeutics Inc. Eyes Future Growth Amidst Current Market Dynamics - StocksToTrade
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study - Insider Monkey
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - GlobeNewswire
Serina Therapeutics Announces FDA Feedback Supports - GlobeNewswire
BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer - GlobeNewswire
Novel Brain Hormone Therapy PT00114 Targets Stress Response: Protagenic's Phase 1 Trial Advances - Stock Titan
Mountain Crest Acquisition Corp. II/Better Therapeutics, Inc. Class Action – Important Settlement Information - Business Wire
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease - Business Wire
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings - Business Wire
Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors - Yahoo Finance
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - The Malaysian Reserve
Allarity Therapeutics Provides Second Quarter 2025 Update, - GlobeNewswire
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - PR Newswire
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-Q Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - Yahoo Finance
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):